Manus Neurodynamica develops the NeuroMotor Pen (NMP), a handheld device with sensor technologies and decision‑support software that non‑invasively records and analyses minute limb and hand motion during drawing and writing movements. The system extracts digital biomarkers to provide objective information on cognitive and motor decline, which the company says yields higher accuracy than clinical rating scales and supports electronic record keeping. Innovate UK awarded Manus a £600,000 grant to fund a two‑year project to optimise and validate NMP for screening dementias, including Alzheimer’s disease. Project work includes fine‑tuning signal‑processing algorithms to extract AD biomarkers, completing clinical validation in 200 patients with early AD, and optimising the data pipeline with integration of other clinical data points and rating scales. Manus will engage 100 people living with AD and their supporters to assess usability and acceptability, and will prepare for clinical deployment with a budget impact analysis. The company plans to roll out NMP later this year for Parkinson’s diagnosis in the UK and Benelux and is progressing regulatory approval efforts to begin selling in the US. Manus Neurodynamica develops the NeuroMotor Pen, a CE-marked digital pen that uses sensors and analytical software to analyse subtle limb and hand movements and provide an objective, non-invasive aid to diagnosis and monitoring. The NeuroMotor Pen is positioned to give early warning of Parkinson’s disease and other neurological conditions. Led by CEO Rutger Zietsma, the company plans to roll out the NeuroMotor Pen later in the year, initially targeting the UK and Benelux markets. Manus is also progressing work to secure regulatory approval to begin sales in the US. The company raised £1.2M in funding to support the product launch. Investors named in the round include the North East Innovation Fund (supported by the European Regional Development Fund and managed by Northstar Ventures), SIS Ventures and Old College Capital. Manus Neurodynamica develops the NeuroMotor Pen (NMP), a digital pen that combines built-in sensors, software, an analytical engine and a Decision Support System to record and analyse limb and hand motion. The device quantifies fine motor skills and creates digital biomarkers to provide objective information about anomalies in movement. The company says the technology can diagnose and monitor Parkinson’s disease and other neuromotor illnesses and could become an inexpensive, non-invasive diagnostic aid. Manus has passed clinical trials with the NHS in the north-east of England and its technology is currently in use by NHS Northumbria and clinicians in the Netherlands. The company says it will use the new funding to grow its business, expand its product list and team, and move towards US clinical trials. The article identifies the company as based in Edinburgh and reports a £750,000 funding boost.

Total raised

$3M

Funding rounds

3

Latest round

Grant

Latest activity

Apr 2021